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Blockade of the renin–angiotensin system (RAS), the standard
treatment for chronic proteinuric nephropathy, slows but
may not halt progression of the disease, particularly when
therapy is started late. Because vasopressin may also play a
role in the progression of renal disease, we measured the
effect of a dual V1a and V2 vasopressin receptor antagonist
(RWJ-676070) alone or combined with angiotensin-converting
enzyme inhibition or angiotensin II type 1 receptor blockade
on proteinuria and renal disease progression during overt
nephropathy. Twenty-one days after renal mass reduction, a
time of established injury, rats were given vehicle, RWJ-
676070, enalapril, losartan, RWJ-676070 plus enalapril, or
losartan in drinking water for an additional 39 days. RWJ-
676070 returned the blood pressure to pre-treatment levels,
which were significantly lower than those in vehicle-treated
rats. Enalapril, losartan, and the combined therapies reduced
blood pressure to a greater extent. RWJ-676070 afforded a
partial antiproteinuric effect, which was enhanced by the
addition of enalapril or losartan. Renal functional impairment,
and glomerular and tubular changes were partially
ameliorated by RWJ-676070; parameters significantly
improved with either enalapril or losartan alone and
improved to a greater extent with the combined therapies.
Our findings suggest that vasopressin receptor antagonists
could be of additional therapeutic value in the treatment of
chronic proteinuric nephropathy.
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Chronic kidney diseases are increasing worldwide and are
emerging as a global threat to human health.1 Progression to
end-stage renal disease is the final common pathway of many
forms of glomerular disease independently of the initial
insult.2 In the past two decades, research in animals and
humans has helped our understanding of the mechanisms of
how chronic kidney diseases progress and has indicated
possible preventive maneuvers.2,3 These studies have estab-
lished that the progressive deterioration of renal function is
the result of compensatory glomerular hemodynamic
changes in response to nephron loss due to the original
insult that, in turn, causes relentless injury of remaining
intact nephrons.3 Glomerular capillary hypertension, origin-
ally serving to maintain ultrafiltration despite fewer
nephrons, impairs the barrier’s size-selective function and
causes excessive protein ultrafiltration in animal models. It
has been suggested that, rather than simply a marker of
damage, abnormally ultrafiltered proteins can be toxic to the
kidney by exerting a nephritogenic effect that would favour
tissue scarring and functional impairment.4,5
Current treatment for proteinuric chronic nephropathies
is based on blockade of the renin–angiotensin system (RAS)
with angiotensin-converting enzyme (ACE) inhibitors and/or
angiotensin type 1 receptor blockers (ARBs) that limit
proteinuria and reduce glomerular filtration rate decline
and risk of end-stage renal disease more effectively than other
antihypertensive treatments.6 Full remission of the disease,
however, is seldom achieved particularly when pharmaco-
logical intervention is started late. Thus, a significant
reduction of the incidence of end-stage renal disease is likely
to be obtained, provided we can improve the current degree
of renoprotection. This goal may be attainable with a more
complex strategy than with a single pharmacological inter-
vention on the RAS.
In addition to the RAS, vasopressin has also been
suggested to have a role in the progression of chronic kidney
disease by increasing intraglomerular capillary pressure7 and
stimulation of mesangial cell proliferation.8 Vasopressin exerts a
variety of biological effects by specific G-protein-coupled
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receptor subtypes, including vascular V1, renal V2, and
hormone-releasing pituitary V3 receptors.
9 Recently, orally
active nonpeptide vasopressin receptor antagonists have been
developed, the potential therapeutic uses of which include
arterial hypertension, hyponatremia, and congestive heart
failure.10–12 Thus, V1 and/or V2 receptor antagonists could
theoretically be included in a multimodal strategy to
implement renoprotection.
This study was designed with the aims to assess (1) the
effect of a dual V1a and V2 vasopressin receptor antagonist
RWJ-67607013,14 on proteinuria and renal disease progres-
sion in rats with renal mass reduction (RMR) starting when
animals had overt nephropathy; and (2) the renoprotective
effect of adding-on V1/V2 receptor antagonist to either the
ACE inhibitor enalapril or the ARB losartan.
Renal mass reduction in rats, which mimics the human
condition of nephron loss, is characterized by severe
hypertension, proteinuria, glomerulosclerosis, and tubuloin-
terstitial damage, associated with progressive renal functional
deterioration.15 Although ACE inhibition is fully effective in
this model when treatment is started soon after surgical
ablation,16 only partial renoprotection is afforded when
animals receive the ACE inhibitor at a phase of established
overt disease.17,18 Similarly, in the same model only partial
benefit can be achieved with ARB at the stage of overt
nephropathy.18
RESULTS
Mortality
By the end of the study, 6 out of the 20 rats with RMR died in
the vehicle group, 5 out of 20 in the group given V1/V2
antagonist alone, 2 out of 20 in the group given enalapril
alone, 2 out of 12 in the group given losartan alone, 3 out of
20 and 1 out of 12 in the group receiving the combination of
V1/V2 antagonist plus enalapril or losartan, respectively. In
the control group, all rats were alive.
Body weight and food intake
In all experimental groups, the animals gained weight with
time (Table 1). However, in the RMR rats the mean values of
body weight were lower than those of controls during the
study period. Thus, at day 21 after surgery, before treatment,
body weight of RMR rats (n¼ 104) and controls (n¼ 14)
averaged 367±5 and 429±11 g, respectively.
At the end of the study, the mean body weight of rats
given vehicle or RWJ-676070 was significantly (Po0.01)
lower than that of control animals. In the group of rats
treated with the combination of RWJ-676070 plus enalapril
or losartan, values were numerically higher than those in
RMR animals treated with single drugs (Table 1).
As shown in Table 1, the mean values of total food intake
of RMR rats given vehicle or V1/V2 antagonist were
numerically lower than those of control rats. Food intake
of RMR rats given enalapril or losartan alone, or combined
with V1/V2 antagonist was similar to that of controls.
Diuresis and water intake
As compared with controls, diuresis was more than double in
RMR rats 21 days after surgery, before treatment (45±1
versus 22±2ml/24 h, Po0.01), and remained significantly
(Po0.01) higher until day 60 (Table 1). No statistical
difference was detected among the groups of RMR rats
during the study. Of note is the fact that in rats given the V1/
V2 antagonist alone or in combination with enalapril or
losartan, the daily urine volume was not further increased as
compared with animals receiving vehicle. In parallel with the
increase in diuresis, the water intake was significantly
(Po0.05) enhanced in all RMR groups as compared with
controls (Table 1).
Serum and urinary electrolytes
Serum Na levels measured at day 60 were similar in RMR
groups and controls, with mean values ranging from
147±0.8 to 151±2mEq/l. At the same time point also
serum K concentration was comparable in all study groups
(average: 6±0.1 to 6±0.3mEq/l). As shown in Table 2, the
urinary Na excretion rate was numerically lower in RMR rats
given vehicle as compared with controls. RWJ-676070
numerically, but not significantly, increased urinary Na
excretion. Actually, the mean values were comparable with
those in control rats. Similarly, enalapril or losartan
treatment normalized the urinary Na excretion. The
combined therapies did not result in any further change in
Na excretion as compared with the single treatments. Urinary
Na concentration in RMR rats was significantly (Po0.01)
lower than control group (Table 2). The mild natriuretic
effect of the V1/V2 antagonist is also supported by the
minimal increase in urinary Na concentration in RMR rats
Table 1 | Body weight, food intake, diuresis, and water intake evaluated in rats with renal mass reduction (RMR) at 60 days
Group Body weight (g) Food intake (g/24 h) Diuresis (ml/24h) Water intake (ml/24 h)
RMR
Vehicle 437±17 22±2 47±3 64±6
RWJ-676070 457±18 24±2 45±4 68±8
Enalapril 483±12 27±1 43±2 63±3
Losartan 478±14 29±1* 45±4 75±5
RWJ-676070+enalapril 490±9 29±1* 42±3 68±4
RWJ-676070+losartan 512±16* 28±2 41±2 73±6
Control 542±16 27±1 22±1 41±2
Values are expressed as mean±s.e. *Po0.05 vs RMR+vehicle. Statistical analysis comparing the control group and the RMR groups is reported in the text.
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given the compound compared with those receiving the
vehicle alone (Table 2), despite similar daily urine volume.
Systolic blood pressure
The time course of systolic blood pressure (SBP) is shown in
Figure 1. Rats with RMR showed a significant (Po0.01)
increase in SBP as compared with controls at day 21 post-
surgery (before starting treatment). In rats given vehicle SBP
further increased during the study (Po0.01 versus control).
Treatment with RWJ-676070 kept SBP at values similar to
pretreatment and significantly lower than those measured in
RMR given vehicle during the 60-day follow-up. Enalapril,
losartan, and the combined therapies reduced SBP to a
greater extent than V1/V2 antagonist alone. In the group of
RMR rats given RWJ-676070 plus enalapril, SBP values were
not different from those of control group during the all study.
Urinary protein excretion
As shown in Figure 2, at day 21 after surgery, all RMR rats
developed proteinuria (Po0.01 versus control) that further
increased during time in the vehicle group. Treatment with
RWJ-676070 caused a 46% reduction of proteinuria with
respect to vehicle at day 30 (Po0.05); proteinuria values of
V1/V2 antagonist-treated rats remained numerically lower
than those of vehicle at day 60 (38% reduction). Enalapril
therapy alone maintained significantly (Po0.01) lower levels
of proteinuria over time than those of vehicle. Combined
administration of V1/V2 antagonist with enalapril resulted in
a further reduction of urinary protein excretion as compared
with mean values in RMR rats given V1/V2 antagonist or
enalapril alone. Notably, at day 30, proteinuria values were
fairly comparable with those measured in control group.
Losartan alone kept proteinuria at levels similar to pretreat-
ment and numerically lower than those of vehicle-treated rats
at day 30; values became significantly different at day 60
(Po0.01). In rats given V1/V2 antagonist plus losartan, the
mean proteinuria levels were numerically lower than those
measured in rats given each agent alone.
Renal function
Renal function progressively declined in RMR rats given
vehicle, as indicated by serum creatinine levels that
significantly increased over controls (day 60: 1.91±0. 20 vs
0.50±0mg per 100ml, Po0.01). Treatment with V1/V2
antagonist partially prevented the increase in serum creati-
nine levels, although a statistical significance was not
achieved (Figure 3). In RMR rats administered enalapril or
losartan alone, serum creatinine levels were significantly
(Po0.01) lower than those in rats given vehicle, but still
higher (Po0.01) than in control group. A further reduction
in serum creatinine concentration was achieved in rats given
the combined therapies (Po0.05 versus control). Overall, a
significant correlation was found between renal function,
serum creatinine, and urinary protein excretion rate
(r¼ 0.798, Po0.001) (Figure 4).
Table 2 | Effect of V1/V2 antagonist on urinary Na excretion
and concentration in renal mass reduction (RMR) rats
Group
Urinary Na excretion
(mEq/day)
Urinary Na
concentration (mEq/l)
RMR
Vehicle 2.6±0.2 57±4
RWJ-676070 3.1±0.2 73±6
Enalapril 3.2±0.1 76±5
Losartan 3.3±0.2 78±8
RWJ-676070+enalapril 3.3±0.2 75±3
RWJ-676070+losartan 3.0±0.1 76±6
Control 3.3±0.2 152±10
Values are expressed as mean±s.e. Statistical analysis comparing the control group
and the RMR groups is reported in the text.
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Figure 1 | Time course of systolic blood pressure (SBP) in
rats with renal mass reduction (RMR) administered vehicle,
the V1/V2 antagonist RWJ-676070, enalapril, losartan,
RWJ-676070 plus enalapril or losartan. Treatment was started
21 days after surgical ablation, when RMR rats developed
hypertension (Po0.01 vs control). Data are mean±s.e. *Po0.05,
**Po0.01 vs vehicle; BPo0.05, BBPo0.01 vs RWJ-676070.
Statistical analysis comparing the control group and the RMR
groups is reported in the text.
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Figure 2 |Time course of urinary protein excretion in rats
with RMR treated from day 21 after surgery with vehicle,
RWJ-676070, enalapril, losartan, RWJ-676070 plus enalapril
or losartan. Data are mean±s.e. *Po0.05, **Po0.01 vs vehicle;
BBPo0.01 vs RWJ-676070 alone. Statistical analysis comparing
the control group and the renal mass reduction (RMR) groups is
reported in the text.
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Renal histology and inflammatory cell infiltrate in the
interstitium
Table 3 reports the results of renal morphological analysis by
light microscopy performed at day 60. RMR rats given vehicle
showed glomerulosclerosis affecting on average 62% of
glomeruli (Po0.01 versus control). Lesions were character-
ized by segmental areas of sclerosis and hyalinosis with
capillary collapsing and adhesion to Bowman’s capsule.
Tubular damage was also documented, consisting of luminal
proteinaceous casts and tubular atrophy (score: 1.4±0.1,
Po0.01 versus control). In RMR rats treated with RWJ-
676070, the glomerular lesions were less diffuse and severe
and the percentage of glomeruli with sclerotic changes
averaged 41% (Po0.05 versus vehicle; Po0.01 versus
control). Tubular damage was also mildly reduced. Enalapril
treatment was associated with a partial but significant
reduction in the percentage of glomeruli with sclerosis (on
average 25%; Po0.01 versus vehicle; Po0.01 versus control).
The combined administration of V1/V2 antagonist and
enalapril further lowered the percentage of sclerotic glomer-
uli to 16% (Po0.01 versus vehicle or V1/V2 antagonist, not
significant versus control) and also significantly ameliorated
tubular damage (Po0.05 versus vehicle). In rats given
losartan, the percentage of glomeruli with sclerotic changes
averaged 32% (Po0.01 versus vehicle; Po0.01 versus
control). Glomerulosclerosis decreased to 23% after the
addition of V1/V2 antagonist to losartan (Po0.01 versus
vehicle; Po0.05 versus control). Tubular damage was mildly
affected by either losartan alone or the combined therapy
(Po0.01 versus control).
As shown in Table 3, a large accumulation of ED-1-
positive monocytes/macrophages was found in the renal
interstitium of RMR rats given vehicle (Po0.01 versus
control). In all groups of RMR-treated rats, the number of
ED-1-positive cells were higher (Po0.01) than that of
control group. RWJ-676070 reduced interstitial infiltrates
by 24% with respect to vehicle-treated rats. Enalapril and
losartan were more effective in limiting to a significant extent
the number of ED-1-positive cells (Po0.01 versus vehicle).
The degree of cell infiltrate in the interstitium was decreased
further by the combination of V1/V2 antagonist and
enalapril, but not with losartan.
Plasma levels of V1/V2 antagonist in RMR rats
At the end of the study, blood samples were collected to
measure plasma concentration of RWJ-676070 in animals
given the drug alone or in combination with the ACE
inhibitor. Plasma levels of the V1/V2 antagonist in RMR rats
given the drug alone averaged 2094±394 ng/ml. In RMR rats
on V1/V2 antagonist plus enalapril, the mean plasma level of
the compound was numerically, but not significantly, lower
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Figure 4 |Correlation between renal function (measured as
serum creatinine levels) and proteinuria evaluated in all the
experimental groups considering values at baseline and at
days 30 and 60 during treatment.
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Figure 3 | Serum creatinine at day 60 in rats with renal mass
reduction (RMR) administered vehicle, RWJ-676070, enalapril,
losartan, RWJ-676070 plus enalapril or losartan. Data are
mean±s.e. **Po0.01 vs vehicle. Statistical analysis comparing the
control group and the RMR groups is reported in the text.
Table 3 | Renal histology and interstitial accumulation of monocytes/macrophages
Group Glomeruli with sclerotic changes (%) Tubular damage (score) ED-1-positive cells (cells/HPF)
RMR
Vehicle 62±5 1.4±0.1 62±3
RWJ-676070 41±6* 1.1±0.1 47±5
Enalapril 25±5** 0.9±0.1 39±4**
Losartan 32±6** 1±0 37±6**
RWJ-676070+enalapril 16±3**BB 0.8±0.1* 32±3**
RWJ-676070+losartan 23±5** 1.1±0.1 38±6**
Control 0 0 12±1
HPF, high-power field; RMR, renal mass reduction.
Values are expressed as mean±s.e. *Po0.05, **Po0.01 vs RMR+vehicle; BBPo0.01 vs RMR+RWJ-676070.
Statistical analysis comparing the control group and the RMR groups is reported in the text.
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than that in animals given the V1/V2 antagonist alone
(1464±261 ng/ml).
DISCUSSION
We found that the V1/V2 antagonist RWJ-676070
13 reduced
systemic blood pressure, afforded partial antiproteinuric
effect, and ameliorated glomerular and tubular damage,
ultimately slowing renal function deterioration, if adminis-
tered as a single agent to rats with RMR. Of note, the therapy
was started when animals already had overt nephropathy
with the aim to interfere with the disease process.
The renoprotective effect of chronic vasopressin receptor
blockade with nonpeptide orally active compounds has been
previously documented in several experimental rat models of
progressive kidney diseases, including adriamycin nephro-
pathy,19,20 spontaneously hypercholesterolemic rats under-
going unilateral nephrectomy,21 streptozotocin-induced
diabetes mellitus,22 and partially nephrectomized, salt-loaded
spontaneously hypertensive rats.23 In all instances, however,
treatment with vasopressin receptor antagonists was started
at the time of induction of kidney disease to prevent the
development of proteinuria and renal structural injury, and
possibly progressive renal function deterioration. In this
study, we showed that the selective blockade of V1/V2
receptors had therapeutic efficacy if started 3 weeks after
five-sixths nephrectomy when overt nephropathy was already
manifested. In a previous report in rats with five-sixths renal
mass ablation, a V1a-antagonist ameliorated renal disease
progression when given 2 weeks after surgery, but was
uneffective when treatment was given as a later intervention
at 6 weeks.24 In this study, the drug was administered
daily by gavage, not in the drinking water as we did, therefore
its effect could be more short-lived. More complete
antagonism of vasopressin activity with the combined
V1/V2 compound could explain the renoprotection we
documented. The present findings open the possibility that
nonpeptide vasopressin receptor antagonists could be of
additional therapeutic value as renoprotective agents in
patients with proteinuric chronic nephropathies. Whether
the beneficial effect of the V1/V2 receptor antagonist was
sustained by blockade of V1, V2 or both receptors, and how
receptor antagonism afforded renoprotection remains ill
defined. In a rat model of progressive nephropathy induced
by adriamycin and accelerated by deoxycorticosterone
acetate-salt hypertension, the V1 antagonist (OPC-21268)
as well as the V2 antagonist (OPC-31260) significantly
reduced proteinuria, as well as glomerular and tubulo-
interstitial injury as compared with the untreated animals.20
Moreover, in streptozotocin-induced diabetic rats, the
development of albuminuria was completely prevented by
chronic antagonism of V2-mediated actions of vasopressin.
22
The importance of V1/V2 receptor antagonism in renopro-
tection is also underlined by the observation that in
Brattleboro rats, deficient in vasopressin, submitted to five-
sixths nephrectomy, the administration of the V2 receptor
agonist DDAVP accelerated the progression of chronic kidney
disease more than that of vasopressin, an agonist of both V1
and V2 receptors.
25
There is evidence showing that the activation of V1
receptors may contribute to glomerular damage by inducing
contraction of mesangial cells,26,27 and vasoconstriction of
glomerular efferent arterioles which enhances glomerular
capillary pressure.7 Studies have suggested that the activation
of V2 receptors at tubular level inhibits tubuloglomerular
feedback as a result of reduction in salt concentration at the
macula densa, secondary to V2-receptor-mediated urine
concentrating process.28,29 Blockade of tubuloglomerular
feedback translates into the elevation of intraglomerular
capillary pressure and eventually glomerular injury.30 In
addition, the evidence of a direct V2 effect on glomerular
hemodynamics is also available, as shown by the fact that the
infusion of the V2 antagonist OPC-31260 to hydropenic rats
given the vasopressin-V2 receptor agonist desmopressin,
normalized glomerular filtration rate compared with vehi-
cle.31 Therefore, the glomerular mechanisms of actions of V1
and V2 receptors would imply that renoprotection afforded
by RWJ-676070 in our model can result from its ability to
block both V1 and V2 receptors causing reduction of
intraglomerular capillary pressure and eventually lowering
abnormal protein traffic through the glomerular capillary
barrier, thus limiting urinary protein excretion and renal
scarring.32
Interestingly, in RMR rats receiving the V1/V2 antagonist,
the daily urine volume was not further increased as compared
with RMR animals receiving the vehicle. The lack of a
diuretic effect of the V1/V2 antagonist could be explained by
the fact that in this rat model the tubular water reabsorption
by the collecting duct principal cells is already largely reduced
due to a marked reduction in aquaporin 2 and 3 expression,
which translates in a marked increase in the daily
urine volume,33 as we found in RMR rats given vehicle. In
this setting, the effect on water reabsorption of the V1/V2
antagonist might be negligible, if any. This would result
in no significant change in the diuresis as compared
with animals receiving the vehicle. Alternatively, but not
exclusively, the possibility exists that the V2 antagonistic
actions at tubular level of the tested V1/V2 antagonist may be
very weak.
On the other hand, we found that V1/V2 antagonism
numerically increased the urinary Na excretion as compared
with vehicle in RMR rats. This finding indicates that the V1/
V2 antagonist inhibited the mild Na tubular reabsorption
occurring in rats undergoing renal mass ablation. This effect
could be attributed to the antagonism of V2 receptor at the
collecting duct. Indeed, evidence is available that in the rats
the V2 agonist dDAVP increased mRNA expression of the
b- and g-subunits of the endothelial sodium channel in renal
collecting ducts.34 This was associated with marked increase
in sodium reabsorption in response to exogenous dDAVP ex
vivo.34 The mild natriuretic effect of the V1/V2 antagonist is
also supported by the minimal increase in urinary Na
concentration in RMR rats given the V1/V2 antagonist
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compared with those given vehicle alone, despite similar
urine volume.
A major finding in this study is that the combined
administrations of the V1/V2 antagonist with RAS inhibitors
were more effective than either treatment alone in protecting
animals from renal damage. Actually, 68% reduction in
urinary protein excretion rate was found in RMR rats after
combined treatment with V1/V2 antagonist and the ACE
inhibitor enalapril with respect to RMR vehicle-treated
animals, as compared with a 38 and 56% reduction observed
with V1/V2 antagonist and enalapril alone, respectively. Renal
function impairment and structural changes of RMR rats
were also consistently ameliorated by the combined therapy.
The effect of the combined treatment with V1/V2 antagonist
and ACE inhibitor on proteinuria, renal function, and
structure was also higher than that with ACE inhibitor
alone, although the difference did not reach statistical
significance. Renoprotection was less effective combining
V1/V2 antagonist with the ARB losartan than with enalapril,
despite comparable blood pressure control.
Pharmacological inhibition of RAS with ACE inhibitors
and ARBs has been shown in the landmark experimental and
clinical studies to limit proteinuria and attenuate decline in
renal function inexorably associated with chronic renal
diseases.35,36 These effects have been attributed to the control
of systemic and intraglomerular hypertension along with
the ability of this class of drugs to limit excess protein
ultrafiltration and its deleterious consequences.2 When given
soon after disease induction, ACE inhibitors consistently
limit hypertension, proteinuria, and renal injury in virtually
all animal models of renal disease.16,37–39 By contrast, when
treatment starts late in the course of the disease at the stage of
overt nephropathy, drugs that antagonize RAS are not
uniformly effective.40–42 Most patients with proteinuric
nondiabetic or diabetic renal disease are actually referred
late or very late to the nephrologist, and in such
circumstances treatment with ACE inhibitors may be of
relatively little value to control disease progression. To model
the human condition, we started the combined treatment
with RAS blockers and the V1/V2 receptor antagonist in rats
with renal mass ablation at the stage of overt nephropathy.
This setting was instrumental to demonstrate for the first
time that the combined therapy did retain therapeutic
effectiveness, when RAS inhibitor alone was no longer
enough. Suppression of the RAS after treatment with either
ACE inhibitors or ARBs remains incomplete.43 A key reason
for this is that these therapies stimulate a reactive increase in
renin activity,44 because they disrupt the short feedback loop
by which angiotensin II normally inhibits the release of renin
from the kidney.45 The reactive plasma renin stimulation by
ACE inhibitors, particularly after long-term use, provides an
explanation for why current RAS inhibitors are sometimes
suboptimal or not effective. Recent evidence indicates that in
mice knockout for V1a receptor the expression of renin in
granule cells of the macula densa was reduced, which led to a
decreased level of plasma renin.46 These findings would imply
that the additional renoprotective effect we observed by
combining ACE inhibitor with the V1/V2 receptor antagonist
in rats with renal mass ablation could be due to a renin defect
secondary to blockade of V1a receptor by RWJ-676070.
However, prolonged treatment with the combined drugs
showed that after the initial decline in proteinuria as
compared with baseline value, there was an escape of the
antiproteinuric effect on the long term, similar to that
documented with ACE inhibitor alone. This suggests that the
renoprotection afforded by RWJ-676070 through inhibition
of renin synthesis is negligible, if any. Thus, the further
beneficial effect of adding-on the V1/V2 receptor antagonist
to RAS inhibitors on renal disease progression could likely be
related to an independent direct effect of the compound
through blockade of V1 and V2 glomerular receptors. As
additional complementary mechanism, the increase in salt
concentration at macula densa secondary to tubular V2
receptor antagonism would result into activation of tubu-
loglomerular feedback and further reduction of intraglomer-
ular capillary pressure.
In conclusion, this study showed that in a severe model of
progressive nephropathy only partially responsive to RAS
blockade, combining the V1/V2 receptor antagonist RWJ-
676070 with RAS inhibitors may further potentiate the
renoprotective effect of RAS blockade alone. Possible targets
of the combined agents’ action are the abnormal glomerular
hemodynamics and the related perm-selective dysfunction,
and indirectly the secondary pathways of glomerular and
tubular interstitial damage triggered by glomerular and
tubular protein overload, which act to perpetuate renal
injury in rats with RMR and overt nephropathy. The
proposed therapeutic approach could add to the available
armamentarium for animals with advanced renal disease in
which RAS inhibitors alone fail to fully prevent progressive
renal injury.
MATERIALS AND METHODS
Animals and experimental design
Male Sprague–Dawley, CD-COBS rats (Charles River, Calco, Italy),
with initial body weights of 275–300 g were used. Animal care and
treatment were conducted in accordance with the institutional
guidelines that are in compliance with national (Decreto Legislativo
n.116, Gazzetta Ufficiale suppl 40, 18 febbraio 1992, Circolare n.8,
Gazzetta Ufficiale 14 luglio 1994) and international laws and policies
(EEC Council Directive 86/609, OJL358-1, December 1987; Guide
for the Care and Use of Laboratory Animals, U.S. National Research
Council, 1996). All animals were housed in a room in which the
temperature was kept constant on a 12-h dark/12-h light cycle and
allowed free access to standard diet containing 20% protein by
weight and tap water. RMR was obtained by right nephrectomy and
ligation of 2 or 3 branches of the main renal artery, according to
Olson.15 Twenty-one days after surgery, when rats had hypertension
and proteinuria, they were allocated to receive the following
treatments in the drinking water: group 1 (n¼ 20) rats given
vehicle (water); group 2 (n¼ 20) rats given the V1/V2 receptor
antagonist RWJ-676070 (Johnson & Johnson Pharmaceutical,
Raritan, NJ, USA),13,14 at the daily dose of 30mg/kg; group 3
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(n¼ 20) rats given the ACE inhibitor enalapril (Sigma-Aldrich,
St Louis, MO, USA) (15mg/l);38 group 4 (n¼ 12) rats given the
ARB losartan (Merck Sharp & Dohme, Rome, Italy) (10mg/kg);
group 5 (n¼ 20) rats treated with the combination of the V1/V2
antagonist and enalapril; and group 6 (n¼ 12) rats treated with the
combination of the V1/V2 antagonist and losartan. An additional
group of sham-operated rats (group 7, n¼ 14) without any
treatment was followed for the same period as controls.
In all groups, SBP was measured at baseline, day 21 after surgery
(before treatment) and day 30 and 60 during treatment, by the
tail-cuff method.47 Urinary protein excretion was monitored at
the same times. Serum creatinine concentration, as an index of
renal function, was measured at baseline, day 30 and 60. At day 60,
serum concentration of Na and K and urinary excretion of Na
were determined. Plasma levels of the V1/V2 antagonist were also
measured (at Johnson & Johnson). Rats were then killed, the kidneys
were removed and renal tissue was processed for morphological
and immunohistochemical studies.
Biochemical parameters
Twenty-four hour urine samples were collected using metabolic
cages, and proteinuria was determined by modified Coomassie blue
G dye-binding assay for proteins with bovine serum albumin as
standard.48. Serum creatinine levels were measured by the Refloron
test (Roche Diagnostics, Indianapolis, IN, USA). Serum and urinary
electrolytes were measured using an autoanalyzer (CX5, Beckman
Instruments, Fullerton, CA, USA).
Renal histology and immunohistochemistry
The removed kidneys were fixed overnight in Duboscq-Brazil,
dehydrated in alcohol, and embedded in paraffin. Kidney samples
were sectioned at 3 mm intervals and the sections were stained with
Masson’s trichrome, hematoxylin and eosin, and periodic-acid Schiff
reagent. Tubular changes (atrophy, casts, and dilatation) were
graded from 0 to 4þ (0, no change; 1þ , changes affecting less than
25% of the sample; 2þ , changes affecting 25–50% of the sample;
3þ , changes affecting 50–75% of the sample; 4þ , changes affecting
75–100% of the sample). Data are expressed as the mean score values
for tubular damage for each animal. At least 100 glomeruli were
examined for each animal and the extent of glomerular damage was
expressed as the percentage of glomeruli presenting sclerotic lesions.
All renal biopsies were analyzed by the same pathologist who was
unaware of the nature of the experimental groups.
Detection of ED-1 antigen was performed on paraffin sections
using a mouse monoclonal antibody (Chemicon, Temecula, CA,
USA) by an alkaline phosphatase-Fast Red technique as previously
described.49 Positive cells were counted in at least 10 randomly
selected high-power microscopic fields (400) per each animal.
Statistical analysis
Data are expressed as mean±s.e. Data were analyzed by analysis of
variance with Bonferroni correction or by the nonparametric
Kruskal–Wallis test for multiple comparisons. Correlation between
serum creatinine levels and proteinuria was calculated by a linear
regression analysis. The statistical significance level was defined as
Po0.05.
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